Efficacy and tolerability of switching to ziprasidone in italian patients with acute exacerbation of schizophrenia: An open-label trial

Pharmacopsychiatry

Volumn 45, Issue 6, 2012, Pages 236-240

  Mencacci, C ^a  

^a FATEBENEFRATELLI HOSPITAL   (Italy)

Author keywords

acute exacerbation; antipsychotic agents; schizophrenia; switch; ziprasidone

Indexed keywords

ALPRAZOLAM; ATYPICAL ANTIPSYCHOTIC AGENT; BENZAMIDE DERIVATIVE; BUTYROPHENONE DERIVATIVE; HALOPERIDOL; LORAZEPAM; LORMETAZEPAN; OLANZAPINE; PHENOTHIAZINE; RISPERIDONE; THIOXANTHENE DERIVATIVE; TRIAZOLAM; UNCLASSIFIED DRUG; ZIPRASIDONE;

ADULT; CARDIOVASCULAR DISEASE; CLINICAL GLOBAL IMPRESSION SCALE; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEART ARRHYTHMIA; HEART DISEASE; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MULTICENTER STUDY; PERIPHERAL NEUROPATHY; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; SCHIZOPHRENIA; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; LONG QT SYNDROME; MALE; MIDDLE AGED; PATIENT PREFERENCE; PIPERAZINES; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; THIAZOLES;

EID: 84866379311     PISSN: 01763679     EISSN: 14390795     Source Type: Journal    
DOI: 10.1055/s-0032-1301884     Document Type: Review

References (21)

1. Vohora D. Atypical antipsychotic drugs: current issues of safety and efficacy in the management of schizophrenia. Curr Opin Investig Drugs: 2007; 8 531 538
2. Weiden P J. Switching in the era of atypical antipsychotics. An updated review. Postgrad Med: 2006; Spec No: 27 44
3. Motlová L, Spaniel F, Höschl C et al. Are there any differences in the efficacy among second generation antipsychotics in the treatment of schizophrenia and related disorders? Ann Clin Psychiatry: 2007; 19 133 143
4. Komossa K, Rummel-Kluge C, Hunger H et al. Ziprasidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev: 2009; 4 CD006627
5. Swainston Harrison T, Scott L J. Ziprasidone: a review of its use in schizophrenia and schizoaffective disorder. CNS Drugs: 2006; 20 1027 1052
6. Haddad P M, Sharma S G. Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs: 2007; 21 911 936
7. Greenberg W M, Citrome L. Ziprasidone for schizophrenia and bipolar disorder: a review of the clinical trials. CNS Drug Rev: 2007; 2 137 177
8. Citrome L. Using oral ziprasidone effectively: the food effect and dose-response. Adv Ther: 2009; 26 739 748
9. th September 2010
10. th September 2010
11. Simpson G M. Benefits of ziprasidone in stable outpatient schizophrenics switched from conventional antipsychotics, olanzapine or risperidone. Int J Neuropsychopharm: 2000; 3 01 S157 S158
12. Harvey P D, Meltzer H Y, Romano S. Improvement in cognition following a switch to open-label ziprasidone from olanzapine, risperidone and conventional antipsychotics. Eur Neuropsychopharm: 2000; 10 03 S288
13. Daniel D G. Improvement in indices of health status following a switch to ziprasidone from conventional and novel antipsychotics. Int J Neuropsychopharm: 2000; 3 01 S159
14. Weiden P J, Daniel D G, Simpson G et al. Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone. J Clin Psychopharmacol: 2003; 23 595 600
15. Weiden P J, Simpson G M, Potkin S G et al. Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia. J Clin Psychiatry: 2003; 64 580 588
16. Stroup T S, Lieberman J A, McEvoy J P et al. CATIE investigators Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry: 2006; 163 611 622
17. Rossi A, Cañas F, Fagiolini A et al. Switching among antipsychotics in everyday clinical practice: focus on ziprasidone. Postgrad Med: 2011; 123 135 159
18. Dunn J, Simpson G M, Fayek M et al. Ziprasidone: long-term post-switch efficacy in schizophrenia. Eur Neuropsychopharmacol: 2004; 14 03 S269 S270
19. Harvey P D, Meltzer H, Simpson G M et al. Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in out patients with schizophrenia. Schizophr Res: 2004; 66 101 113
20. Lieberman J A, Stroup T S, McEvoy J P et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med: 2005; 353 1209 1223
21. Kessing L V, Thomsen A F, Mogensen U B et al. Treatment with antipsychotics and the risk of diabetes in clinical practice. Br J Psychiatry: 2010; 197 266 271